Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer

Friday, May 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 3 ROSELLA trial results were presented at the American Society of Clinical Oncology Annual Meeting, highlighting the overall survival subgroup analyses for patients with platinum-resistant ovarian cancer. The study compares the efficacy of relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy, focusing on patients with prior taxane use. The findings suggest potential benefits of the combination therapy.
Price reaction · baseline $69.49 (2026-05-29 close) · hit after-hours · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents promising results for relacorilant in combination with nab-paclitaxel.
  • The trial focuses on a specific patient subgroup, enhancing treatment personalization.
  • Presentation at a major conference indicates recognition and interest in the findings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

Presented : American Society of Clinical Oncology Annual Meeting , 29 May 2026, Chicago, IL
Presenter : Lucy Gilbert, MD , MSc , FRCOG
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Presentation
The post Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer appeared first on Corcept Therapeutics .

Frequently Asked Questions

What was the focus of the ROSELLA trial?

The ROSELLA trial focused on the efficacy of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Where were the trial results presented?

The trial results were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.

Who presented the ROSELLA trial findings?

The findings were presented by Lucy Gilbert, MD, MSc, FRCOG.

What does the trial compare?

The trial compares relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare relacorilant nab-paclitaxel ovarian cancer ASCO 2026
Last updated: May 29, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
mifepristone+ fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →